Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShort-Term Debt repayments
Ratios

Harvard Bioscience (HBIO) Other Gross PP&E Adjustments (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Other Gross PP&E Adjustments for 15 consecutive years, with -$8.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments fell 7.68% to -$8.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$8.0 million, a 7.68% decrease, with the full-year FY2024 number at $14.2 million, up 8.82% from a year prior.
  • Other Gross PP&E Adjustments was -$8.0 million for Q3 2025 at Harvard Bioscience, up from -$8.9 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $14.2 million in Q4 2024 to a low of -$11.8 million in Q1 2021.
  • A 5-year average of -$3.4 million and a median of -$6.9 million in 2022 define the central range for Other Gross PP&E Adjustments.
  • Peak YoY movement for Other Gross PP&E Adjustments: tumbled 256.47% in 2021, then soared 44.45% in 2023.
  • Harvard Bioscience's Other Gross PP&E Adjustments stood at $10.4 million in 2021, then grew by 15.57% to $12.0 million in 2022, then increased by 9.08% to $13.1 million in 2023, then grew by 8.82% to $14.2 million in 2024, then crashed by 155.9% to -$8.0 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Other Gross PP&E Adjustments are -$8.0 million (Q3 2025), -$8.9 million (Q2 2025), and -$8.0 million (Q1 2025).